CO6710911A2 - ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino. - Google Patents

((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino.

Info

Publication number
CO6710911A2
CO6710911A2 CO13090555A CO13090555A CO6710911A2 CO 6710911 A2 CO6710911 A2 CO 6710911A2 CO 13090555 A CO13090555 A CO 13090555A CO 13090555 A CO13090555 A CO 13090555A CO 6710911 A2 CO6710911 A2 CO 6710911A2
Authority
CO
Colombia
Prior art keywords
cancer
dichloropyridin
indazol
pyrazol
ethoxy
Prior art date
Application number
CO13090555A
Other languages
English (en)
Inventor
Benjamin Alan Diseroad
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6710911(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6710911A2 publication Critical patent/CO6710911A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al cOmpUCstO ((R)-(E)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4- i1)etoxi)- 11 l-indazol-3-il)vinil)- 11 1-pirazol- 1 -il)etanol cristalino y a derivados del mismo que actúan como potentes inhibidores del receptor de factor de crecimiento del fibroblasto FGFR que tienen actividad en el tratamiento de diferentes tipos de cáncer seleccionados del grupo que consiste en cáncer de mama, cáncer de pulmón de células no pequeñas (NSCL). cáncer de vejiga, cáncer gástrico, cáncer pancreático, cáncer de próstata, cáncer de colon, micloma múltiple, cáncer hepático, melanoma. cáncer de cabeza y cuello, cáncer de tiroides, cáncer de células renales, glioblastoma, y cáncer testicular.
CO13090555A 2010-10-05 2013-04-08 ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino. CO6710911A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38991110P 2010-10-05 2010-10-05

Publications (1)

Publication Number Publication Date
CO6710911A2 true CO6710911A2 (es) 2013-07-15

Family

ID=44999860

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13090555A CO6710911A2 (es) 2010-10-05 2013-04-08 ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino.

Country Status (35)

Country Link
US (1) US8530665B2 (es)
EP (1) EP2625175B1 (es)
JP (1) JP5940547B2 (es)
KR (1) KR101527661B1 (es)
CN (1) CN103153983B (es)
AR (1) AR083091A1 (es)
AU (1) AU2011312485B2 (es)
BR (1) BR112013006336A2 (es)
CA (1) CA2813329C (es)
CL (1) CL2013000884A1 (es)
CO (1) CO6710911A2 (es)
DK (1) DK2625175T3 (es)
DO (1) DOP2013000072A (es)
EA (1) EA021817B1 (es)
EC (1) ECSP13012539A (es)
ES (1) ES2558777T3 (es)
HK (1) HK1184147A1 (es)
HR (1) HRP20151299T1 (es)
HU (1) HUE026379T2 (es)
IL (1) IL224850A (es)
JO (1) JO3062B1 (es)
MA (1) MA34552B1 (es)
ME (1) ME02307B (es)
MX (1) MX2013003907A (es)
NZ (1) NZ608482A (es)
PE (1) PE20140252A1 (es)
PL (1) PL2625175T3 (es)
PT (1) PT2625175E (es)
RS (1) RS54457B1 (es)
SG (1) SG188286A1 (es)
SI (1) SI2625175T1 (es)
TW (1) TWI418554B (es)
UA (1) UA111725C2 (es)
WO (1) WO2012047699A1 (es)
ZA (1) ZA201301560B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
SG10201610416TA (en) 2012-06-13 2017-01-27 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MX2020004108A (es) 2015-02-20 2022-01-03 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111705099B (zh) * 2020-07-01 2022-03-08 天津药明康德新药开发有限公司 一种(s)-1-(3,5-二氯吡啶-4-取代)乙醇的制备方法
CA3202770A1 (en) * 2020-12-17 2022-06-23 Blossomhill Therapeutics, Inc. Macrocycles and their use
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
EA006711B1 (ru) * 2000-09-11 2006-02-24 Чирон Корпорейшн Хинолиноновые производные в качестве ингибиторов тирозинкиназы
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
RU2324692C1 (ru) * 2004-03-17 2008-05-20 Пфайзер Инк. Полиморфные и аморфные формы {2-фтор-5-[3-((е)-2-пиридин-2-илвинил)-1н-индазол-6-иламино]фенил}амида 2,5-диметил-2н-пиразол-3-карбоновой кислоты
JP4746299B2 (ja) * 2004-07-16 2011-08-10 ジュズ インターナショナル ピーティーイー エルティーディー 金属酸化物粉末の製造方法
JP2006163651A (ja) 2004-12-03 2006-06-22 Sony Computer Entertainment Inc 表示装置、表示装置の制御方法、プログラム及びフォントデータ
US20060160863A1 (en) * 2005-01-05 2006-07-20 Agouron Pharmaceuticals, Inc. Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2008122858A2 (en) * 2007-04-05 2008-10-16 Pfizer Products Inc. Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
JO2860B1 (en) * 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds

Also Published As

Publication number Publication date
TW201249826A (en) 2012-12-16
HRP20151299T1 (hr) 2016-01-01
AU2011312485A1 (en) 2013-03-07
US8530665B2 (en) 2013-09-10
TWI418554B (zh) 2013-12-11
AR083091A1 (es) 2013-01-30
PL2625175T3 (pl) 2016-04-29
ES2558777T3 (es) 2016-02-08
JO3062B1 (ar) 2017-03-15
CL2013000884A1 (es) 2013-10-18
PT2625175E (pt) 2016-01-22
EP2625175B1 (en) 2015-11-18
HUE026379T2 (en) 2016-06-28
KR101527661B1 (ko) 2015-06-09
DOP2013000072A (es) 2013-08-15
CN103153983B (zh) 2014-11-05
US20120083511A1 (en) 2012-04-05
SG188286A1 (en) 2013-04-30
EA201390275A1 (ru) 2013-07-30
CA2813329A1 (en) 2012-04-12
CN103153983A (zh) 2013-06-12
SI2625175T1 (sl) 2016-01-29
PE20140252A1 (es) 2014-03-12
MA34552B1 (fr) 2013-09-02
JP2013538875A (ja) 2013-10-17
JP5940547B2 (ja) 2016-06-29
EA021817B1 (ru) 2015-09-30
ME02307B (me) 2016-06-20
RS54457B1 (en) 2016-06-30
IL224850A (en) 2016-09-29
HK1184147A1 (en) 2014-01-17
EP2625175A1 (en) 2013-08-14
CA2813329C (en) 2015-05-26
NZ608482A (en) 2014-03-28
ZA201301560B (en) 2014-08-27
UA111725C2 (uk) 2016-06-10
WO2012047699A1 (en) 2012-04-12
AU2011312485B2 (en) 2014-09-04
MX2013003907A (es) 2013-06-03
KR20130052680A (ko) 2013-05-22
BR112013006336A2 (pt) 2019-09-24
ECSP13012539A (es) 2013-06-28
DK2625175T3 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
CO6710911A2 (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino.
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
IL220155B (en) History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors
IL231025A (en) 1-pyrazolyl-3 - (4 - ((2-anilinopyrimidine-4-yl) oxy) methylated-1-yl) Oriase for use as kinase inhibitors map 38p
NZ593114A (en) Compounds comprising benzimidazolyl, pyrimidinyl, and pyridinyl moieties which are useful as protein kinase inhibitors
EP2550266A4 (en) HETEROCYCLIC COMPOUNDS FOR KINASE INHIBITION
UA101611C2 (ru) СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
HK1156627A1 (en) Picolinamide derivatives as kinase inhibitors
NZ611314A (en) Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
SI2321295T1 (sl) Derivati 4-(piridin-4-il)-1H-(1,3,5,)triazin-2-ona kot inhibitorji GSK3-beta za zdravljenje nevrodegenerativnih bolezni
MX352975B (es) Piridina y derivados de pirazina.
TW201000488A (en) Heterocyclic derivatives
MX363609B (es) Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.
MX345127B (es) Derivados de tiazol.
MX348815B (es) Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo.
MX2016007810A (es) Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa.
BR112015021324A2 (pt) derivados de 6-[4-(1h-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de atividade de quinase
UA109942C2 (ru) Производные 2-амино-3-(имидазол-2-ил)-пиридин-4-она и их применение как ингибиторов киназы рецептора vegf
MX2012013527A (es) Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas.
AR092772A1 (es) Derivado de 7-azaindol
MX2015012600A (es) Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
MX345142B (es) Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina.
GB2514285A (en) Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
NZ623098A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
TN2013000142A1 (en) Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor